Overview of Concerta
Concerta, also known as methylphenidate hydrochloride, is a central nervous system (CNS) stimulant used primarily for the treatment of attention deficit hyperactivity disorder (ADHD) in children aged 6 years and above, as well as in adolescents and adults up to the age of 65. It is formulated as extended-release tablets and capsules for oral administration[1].
Current Market Landscape
The global ADHD market, which includes Concerta, is experiencing a mixed bag of trends. Here are some key points:
-
Global ADHD Market Size: The global ADHD market was valued at USD 15.8 billion in 2023 and is projected to grow at a CAGR of over 5.1% from 2024 to 2032, reaching USD 24.6 billion by the end of the forecast period[3].
-
Regional Performance: The U.S. ADHD market is expected to grow at a 5.1% CAGR, reaching USD 10.2 billion by 2032. Other regions, such as Germany, the Asia Pacific, and Brazil, are also experiencing significant growth[3].
Challenges and Drivers
Market Decline in 7MM
Despite the overall growth in some regions, the ADHD market across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is forecasted to decline at a negative CAGR of 0.9% from $11.9 billion in 2022 to $10.9 billion in 2032. This decline is primarily driven by patent expiries and the anticipated launch of generics in several countries[2].
Patent Expiries and Generics
The expiration of patents for key ADHD drugs, including those related to methylphenidate, and the subsequent launch of generic versions are significant barriers to market growth. Generics, particularly for lisdexamfetamine dimesylate, are expected to see high uptake, limiting the sales of branded products like Concerta[2].
Pipeline Agents
Four late-stage pipeline agents targeting core ADHD symptoms are expected to launch in the US market by 2026. These include Cingulate’s CTx-1301, Axsome Therapeutic’s solriamfetol hydrochloride, Otsuka’s centanafadine SR, and Neurocentria’s NRCT-101SR. While these agents may drive some market growth, they are not expected to significantly improve efficacy over current products but rather offer differentiation in terms of duration of action and side effect reduction[2].
Sales Projections for Concerta
Impact of Patent Expiries
Given the patent expiries and the rise of generics, the sales of Concerta are likely to decline. As generics become more available, they will compete directly with Concerta, potentially reducing its market share and sales.
Market Share and Competition
Concerta faces competition not only from generics but also from other branded products. The launch of new pipeline agents, although not expected to significantly outperform current treatments, will still compete for market share. Key opinion leaders (KOLs) have expressed a preference for established products over new entrants due to the perception that new products do not offer substantial benefits over existing treatments[2].
Regional Sales
In regions where generics are not yet widely available, Concerta may continue to see stable sales. However, in markets like the US, Germany, Spain, the UK, and Japan, where generics are anticipated to launch, sales are likely to decline.
Financial Performance of Johnson & Johnson
Johnson & Johnson, the manufacturer of Concerta, reported a 2.3% increase in sales to $21.4 billion in Q1 2024. However, the specific performance of Concerta within this broader financial context is not detailed. The overall pharmaceutical segment of Johnson & Johnson is subject to various market dynamics, including the impact of generics and new product launches[5].
Key Takeaways
- Market Decline: The ADHD market in the 7MM is expected to decline due to patent expiries and the launch of generics.
- Competition: Concerta faces competition from generics and new pipeline agents, which may reduce its market share.
- Regional Variations: Sales of Concerta will vary by region, with declines expected in areas where generics are launched.
- Pipeline Agents: New pipeline agents may offer some growth but are not expected to significantly outperform current treatments.
- Market Size: The global ADHD market is growing, but the 7MM segment is declining.
FAQs
1. What is Concerta used for?
Concerta, or methylphenidate hydrochloride, is used for the treatment of attention deficit hyperactivity disorder (ADHD) in children aged 6 years and above, as well as in adolescents and adults up to the age of 65[1].
2. Why is the ADHD market in the 7MM declining?
The ADHD market in the 7MM is declining due to patent expiries and the anticipated launch of generics, which will reduce the sales of branded products like Concerta[2].
3. What new pipeline agents are expected to launch in the US ADHD market?
Four late-stage pipeline agents—Cingulate’s CTx-1301, Axsome Therapeutic’s solriamfetol hydrochloride, Otsuka’s centanafadine SR, and Neurocentria’s NRCT-101SR—are expected to launch in the US market by 2026[2].
4. How will the launch of generics affect Concerta sales?
The launch of generics will significantly impact Concerta sales by providing cheaper alternatives, which are likely to attract patients and reduce the market share of Concerta[2].
5. What is the projected growth rate of the global ADHD market?
The global ADHD market is projected to grow at a CAGR of over 5.1% from 2024 to 2032, reaching USD 24.6 billion by the end of the forecast period[3].
Sources
- GlobalData: Net Present Value Model: Concerta/Methylphenidate - Market Analysis.
- Clinical Trials Arena: ADHD market forecast to decline by $1bn between 2022 and 2032.
- GMI Insights: Attention Deficit Hyperactivity Disorder Market Share, 2024-2032.
- PR Newswire: Attention Deficit Hyperactivity Disorder Drugs Market to Record 6.44% Y-o-Y Growth Rate in 2021.
- Johnson & Johnson Investor Relations: Johnson & Johnson Reports Q1 2024 Results.
